Handelsbanken Fonder AB lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 632,446 shares of the company’s stock after selling 500 shares during the quarter. Johnson & Johnson accounts for about 1.6% of Handelsbanken Fonder AB’s portfolio, making the stock its 12th largest position. Handelsbanken Fonder AB’s holdings in Johnson & Johnson were worth $81,048,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Rational Advisors LLC raised its stake in shares of Johnson & Johnson by 100.7% during the first quarter. Rational Advisors LLC now owns 15,440 shares of the company’s stock valued at $1,979,000 after acquiring an additional 7,748 shares in the last quarter. Wesbanco Bank Inc. raised its stake in shares of Johnson & Johnson by 13.2% during the first quarter. Wesbanco Bank Inc. now owns 255,882 shares of the company’s stock valued at $32,792,000 after acquiring an additional 29,897 shares in the last quarter. EagleClaw Capital Managment LLC raised its stake in shares of Johnson & Johnson by 6.4% during the first quarter. EagleClaw Capital Managment LLC now owns 13,395 shares of the company’s stock valued at $1,715,000 after acquiring an additional 800 shares in the last quarter. Moors & Cabot Inc. raised its stake in shares of Johnson & Johnson by 3.2% during the first quarter. Moors & Cabot Inc. now owns 138,329 shares of the company’s stock valued at $17,727,000 after acquiring an additional 4,259 shares in the last quarter. Finally, Xact Kapitalforvaltning AB raised its stake in shares of Johnson & Johnson by 5.6% during the first quarter. Xact Kapitalforvaltning AB now owns 524,721 shares of the company’s stock valued at $67,243,000 after acquiring an additional 27,775 shares in the last quarter. Institutional investors and hedge funds own 66.80% of the company’s stock.

Several analysts have recently weighed in on the stock. ValuEngine downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, June 12th. Finally, Sanford C. Bernstein assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and an average target price of $142.34.

Shares of JNJ stock opened at $139.36 on Thursday. The firm has a market cap of $368.42 billion, a PE ratio of 19.09, a price-to-earnings-growth ratio of 2.09 and a beta of 0.69. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.32.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.06 by $0.04. The business had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The business’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.83 earnings per share. analysts predict that Johnson & Johnson will post 8.14 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th were given a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.58%. The ex-dividend date of this dividend was Monday, August 27th. Johnson & Johnson’s payout ratio is presently 49.32%.

In other news, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.